Results from the early manifest treatment arm (cohort B1, N=179) in a Phase 2 clinical trial, SIGNAL, evaluating Vaccinex’s (NASDAQ:VCNX) lead candidate pepinemab in early manifest and prodromal Huntington’s disease (HD) patients failed to meet expectations.
Specifically, pepinemab failed to sufficiently separate from placebo on either co-primary efficacy endpoint, two cognitive assessment measures called Huntington’s Disease Cognitive Assessment Battery and Clinical Global Impression of Change (CGIC).
On a positive note, pepinemanb, a humanized monoclonal antibody that blocks the signaling of a protein called SEMA4D that plays a key role in the migration and function of immune and inflammatory cells, was well-tolerated with low discontinuation rates over the extended 18-month treatment period.
A new collaboration with Merck (NYSE:MRK) testing the combination of pepinemab and Keytruda (pembrolizumab) in head and neck cancer patients should launch in early 2021.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.